2061-P: Glycemic Outcomes and Patient Satisfaction with Virtual Insulin Pump Training in Type 1 Diabetes: Karaz Academy Data across Five Regions of Saudi Arabia

Introduction and Objective: Access to automated insulin delivery (AID) systems in remote areas is limited by shortage of trained specialists. We evaluated glucose levels, insulin delivery patterns, user behaviors, and training-related patient satisfaction over 6 months among PWT1D who attended Karaz virtual training program, the first national, virtually delivered, structured insulin pump training program designed to onboard patients onto AID therapy across Saudi Arabia (SA) Methods: We retrospectively analyzed pump/CGM data from the first 98 Karaz app users from five regions of SA who completed the Karaz virtual pump training in 2025, initiated AID therapy, and had at least 3 months of available pump/CGM data. Data were assessed at week 1 and months 1, 3, and 6. Logistic regression was used to identify early CGM predictors of achieving the “double target” of TIR>70% and TBR<4% by month 3. Patient satisfaction was assessed using a post-training survey Results: Participants had a mean age of 19 years and 56% were female. From week 1 to month 6, CGM metrics improved as follows: TIR: 62 to 75%; TAR>250: 12 to 5%; TAR>180: 23 to 18% (all p<0.05); and GRI: 45 to 27 (p>0.05). AutoMode utilization increased from 15% at week 1 to 97% at month 6 (p<0.05). Having TIR>70%, GRI<20, and GRI 21-40 at month 1 were significant predictors of achieving the double target by month 3 after adjustment for age, sex, and pump setting (ORs [95% CI]: 10.15 [3.13-32.91]; 56.01 [5.96-526.16]; and 41.87 [7.45-235.33]; respectively). Overall, 86.6% of participants reported being extremely satisfied with the duration of the training; and 87.5% stated they would recommend the program to others Conclusion: Initiation of AID therapy through a national virtual insulin pump training program was associated with sustained improvements in CGM outcomes and high autoMode use and patient satisfaction. Our findings support virtual pump training as an effective strategy to expand equitable access to AID therapy in regions with limited availability of pump specialists Disclosure M.E. Al-Sofiani: Speaker's Bureau; Ended; Medtronic, Dexcom, Inc. Research Support; Current; Dexcom, Inc. Research Support; Ended; Medtronic. Speaker's Bureau; Ended; Insulet Corporation, Abbott Diabetes, Sanofi. M. Alsufiani: None. Y.K. Almutairi: None. S.K. Alharthi: None. L. Alhussain: None. A. Alaskar: None. A.L. Alsakhri: None. F.B. Albedaiwi: None. R.K. Alduraibi: None. H.S. Alshelowi: None. S. Albalwi: None. E. Allababidi: None. S. Albalawi: None.